FDA eyes Nexium, Prilosec for heart risks with early communication
The Food and Drug Administration flagged potential cardiovascular risks with AstraZenecas Nexium and its predecessor, Prilosec, but said it has not yet established an increased risk and discouraged doctors and patients from discontinuing use of the drugs.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.